Heron Therapeutics, Inc. (HRTX)
NasdaqCM
Price as at 30 Sept 2026, 23:12 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Heron Therapeutics, Inc. trades at $0.31. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$1.74M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$1.01M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$663.2K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$643.1K · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$113.7K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in HRTX
Trades in HRTX disclosed by members of Congress and executive-branch officials, latest first:
- Ashley Hinson Arenholz · HouseSell · $1,001 - $15,000 · traded 31 Mar 2021 · disclosed 5 Apr 2021
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own HRTX?
6 of the institutions we track reported a position in HRTX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its HRTX data?
Fundamentals for HRTX come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 23:12 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for HRTX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.